Oncology care company Thyme Care has raised $97 million in a Series D funding round backed by major insurers Humana and CVS Health, as well as JPMorgan’s Morgan Health division.
The round also drew support from Texas Oncology and Houston-based Memorial Hermann Health System, according to a Sept. 25 news release.
The Nashville-based startup was founded in 2020 and partners with health plans, employers, and providers to manage cancer care under value-based arrangements. Thyme said it now manages more than $5 billion in oncology spend, has reached profitability, and has expanded access to 8 million people nationwide through new Medicare, commercial, and employer contracts. The company works with more than 1,000 oncologists to reduce administrative burden, coordinate care, and provide patient support.
With the new capital, Thyme Care plans to scale its operations and expand use of AI in its care model. The company has now raised a total of $275 million.
At the Becker's 5th Annual Fall Payer Issues Roundtable, taking place November 2–3 in Chicago, payer executives and healthcare leaders will come together to discuss value-based care, regulatory changes, cost management strategies and innovations shaping the future of payer-provider collaboration. Apply for complimentary registration now.
